tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2024 Jul 8;11(7)
fae380.
doi: 10.1093/ofid/ofae380. eCollection 2024 Jul. Similar Limited Protection Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection in Vaccinated Individuals With HIV and Comparable Controls
Myrthe L Verburgh[SUP] 1 2 3 [/SUP], Anders Boyd[SUP] 1 2 4 5 [/SUP], Maarten F Schim van der Loeff[SUP] 1 2 5 [/SUP], Margreet Bakker[SUP] 2 6 [/SUP], Ferdinand W N M Wit[SUP] 1 2 4 [/SUP], Marc van der Valk[SUP] 1 2 4 [/SUP], Marloes Grobben[SUP] 2 6 [/SUP], Lisa van Pul[SUP] 2 7 [/SUP], Khadija Tejjani[SUP] 2 6 [/SUP], Jacqueline van Rijswijk[SUP] 2 6 [/SUP], Marit J van Gils[SUP] 2 6 [/SUP], Neeltje A Kootstra[SUP] 2 7 [/SUP], Lia van der Hoek[SUP] 2 6 [/SUP], Peter Reiss[SUP] 1 2 3 8 [/SUP]; AGEhIV Cohort Study
Collaborators, Affiliations
Background: Little is known about the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron infection in people with human immunodeficiency virus (HIV; PWH) with vaccine-induced or hybrid immunity. We assessed the incidence of Omicron infection in 209 AGE[SUB]h[/SUB]IV coronavirus disease 2019 substudy participants with well-controlled HIV on antiretroviral therapy and 280 comparable controls, who had received at least the primary vaccination series.
Methods: From September 2020 onward, participants were assessed every 6 months for the incidence of SARS-CoV-2 infection, per SARS-CoV-2 nucleocapsid antibody assay or self-reported positive antigen or polymerase chain reaction test. Between 1 January and 31 October 2022, the cumulative incidence of Omicron infection and associated risk factors were estimated using a conditional risk-set Cox proportional hazards model.
Results: The cumulative incidence of a first Omicron infection was 58.3% by 31 October 2022, not significantly different between groups. HIV status was not independently associated with acquiring Omicron infection. Former and current smoking, as well as an increased predicted anti-spike immunoglobulin G titer were significantly associated with a lower risk of Omicron infection. The majority of infections were symptomatic, but none required hospitalization.
Conclusions: People with well-controlled HIV and controls in our cohort experienced a similarly high proportion of Omicron infections. More booster vaccinations significantly reduced the risk of infection. Clinical Trial Registration. NCT01466582.
Keywords: HIV; Omicron variant; SARS-CoV-2; incidence; serology.
. 2024 Jul 8;11(7)
fae380.doi: 10.1093/ofid/ofae380. eCollection 2024 Jul. Similar Limited Protection Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection in Vaccinated Individuals With HIV and Comparable Controls
Myrthe L Verburgh[SUP] 1 2 3 [/SUP], Anders Boyd[SUP] 1 2 4 5 [/SUP], Maarten F Schim van der Loeff[SUP] 1 2 5 [/SUP], Margreet Bakker[SUP] 2 6 [/SUP], Ferdinand W N M Wit[SUP] 1 2 4 [/SUP], Marc van der Valk[SUP] 1 2 4 [/SUP], Marloes Grobben[SUP] 2 6 [/SUP], Lisa van Pul[SUP] 2 7 [/SUP], Khadija Tejjani[SUP] 2 6 [/SUP], Jacqueline van Rijswijk[SUP] 2 6 [/SUP], Marit J van Gils[SUP] 2 6 [/SUP], Neeltje A Kootstra[SUP] 2 7 [/SUP], Lia van der Hoek[SUP] 2 6 [/SUP], Peter Reiss[SUP] 1 2 3 8 [/SUP]; AGEhIV Cohort Study
Collaborators, Affiliations
- PMID: 39070044
- PMCID: PMC11273239
- DOI: 10.1093/ofid/ofae380
Background: Little is known about the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron infection in people with human immunodeficiency virus (HIV; PWH) with vaccine-induced or hybrid immunity. We assessed the incidence of Omicron infection in 209 AGE[SUB]h[/SUB]IV coronavirus disease 2019 substudy participants with well-controlled HIV on antiretroviral therapy and 280 comparable controls, who had received at least the primary vaccination series.
Methods: From September 2020 onward, participants were assessed every 6 months for the incidence of SARS-CoV-2 infection, per SARS-CoV-2 nucleocapsid antibody assay or self-reported positive antigen or polymerase chain reaction test. Between 1 January and 31 October 2022, the cumulative incidence of Omicron infection and associated risk factors were estimated using a conditional risk-set Cox proportional hazards model.
Results: The cumulative incidence of a first Omicron infection was 58.3% by 31 October 2022, not significantly different between groups. HIV status was not independently associated with acquiring Omicron infection. Former and current smoking, as well as an increased predicted anti-spike immunoglobulin G titer were significantly associated with a lower risk of Omicron infection. The majority of infections were symptomatic, but none required hospitalization.
Conclusions: People with well-controlled HIV and controls in our cohort experienced a similarly high proportion of Omicron infections. More booster vaccinations significantly reduced the risk of infection. Clinical Trial Registration. NCT01466582.
Keywords: HIV; Omicron variant; SARS-CoV-2; incidence; serology.